摘要
绿原酸(CGA)显示了肝癌、乳腺癌和皮肤癌的治疗可能性。与CGA刺激的癌细胞表现出差异表达的转录因子和调节分子,但分子的分子靶标是未知的。对CGA生原体的元素与Curcumin叠加了0.90最大公共子结构分。分子模拟研究进一步表明,CGA与PKC与氨基酸残基结合位点广泛互动C1B域。它结合PKC是浓度依赖性解离常数KD,28.84±3.95μM. pkc-cga复杂稳定,失真最小的三维结构和维持氢键配体和受体之间的模拟期间。与CGA刺激的细胞会导致从细胞质到质膜12.1°C 0.56% PKC易位。它扰乱了细胞周期使癌细胞在G1期S期细胞减少。绿原酸具有杀灭癌细胞以剂量依赖的方式与75.88±4.54μμg/ml和52.5±4.72μg/mL对MDA-MB-231和MCF-7细胞的IC50分别为。它在肿瘤细胞中诱导细胞凋亡的AO /溴化乙锭染色和DNA梯状条带明显降解给。在癌细胞凋亡的线粒体途径中涉及的线粒体膜电位和释放进入细胞质减少,支持细胞。因此,目前的研究已经建立了PKC作为一个重要的信号分子所观察到的抗癌作用的CGA,并提供动力,设计更好的CGA类似物,提高抗癌潜力对恶性肿瘤。
关键词: 激动剂,肿瘤,细胞周期,姜黄素,细胞色素C,对接,线粒体,蛋白激酶C,PMA,易位。
Current Molecular Medicine
Title:Evidence of PKC Binding and Translocation to Explain the Anticancer Mechanism of Chlorogenic Acid in Breast Cancer Cells
Volume: 17 Issue: 1
关键词: 激动剂,肿瘤,细胞周期,姜黄素,细胞色素C,对接,线粒体,蛋白激酶C,PMA,易位。
摘要: Chlorogenic acid (CGA) exhibits potentials towards liver, breast and skin cancer. Cancer cells stimulated with CGA exhibits differential expression of transcriptional factors and regulatory molecules but the molecular target of the molecule is not known. Superposition of biophoric elements of CGA with Curcumin gives maximum common substructure score of 0.90. Molecular modeling studies further suggest that CGA fits into the C1b domain of PKC with extensive interaction with residues lining binding site. It binds PKC in a concentration dependent manner with dissociation constant KD, 28.84±3.95 μM. PKC-CGA complex is stable with minimal distortion to the 3-D structure and maintains the hydrogen bonding between ligand and receptor during simulation period. Cells stimulated with CGA causes 12.1 ± 0.56% PKC translocation from the cytosol to the plasma membrane. It disturbs the cell cycle and arrest the cancer cell at the G1 phase with a reduction in S-phase. Chlorogenic acid exhibits killing of cancer cells in a dose-dependent manner with an IC50 of 75.88 ± 4.54μg/ml and 52.5 ± 4.72μg/ml towards MDAMB-231 and MCF-7 cells respectively. It induces apoptosis in cancer cells as evident by AO/EtBr staining and degradation of genomic DNA to give a laddering pattern. Apoptosis in cancer cells involves mitochondrial pathway as supported by a reduction in mitochondrial potentials and release of cyt-C into the cytosol. Hence, the current study has established PKC as an important signaling molecule to the observed anti-cancer effects of CGA and provides the impetus to design better CGA analogs for improved anti-cancer potential against the malignant tumor.
Export Options
About this article
Cite this article as:
Evidence of PKC Binding and Translocation to Explain the Anticancer Mechanism of Chlorogenic Acid in Breast Cancer Cells, Current Molecular Medicine 2017; 17 (1) . https://dx.doi.org/10.2174/1566524017666170209160619
DOI https://dx.doi.org/10.2174/1566524017666170209160619 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Guanine Content of MicroRNAs is Associated with their Tumor- Suppressive and Oncogenic Roles in Lung and Breast Cancers
MicroRNA A Potential Role of Diet in Modulating Peroxisome Proliferator-Activated Receptor (PPAR)-Mediated Signalling in Arthritis
Current Rheumatology Reviews Ghrelin: A Molecular Target for Weight Regulation, Glucose and Lipid Metabolism
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Patent Perspective for Potential Antioxidant Compounds-Rutin and Quercetin
Recent Patents on Nanomedicine Repositioning the Old Fungicide Ciclopirox for New Medical Uses
Current Pharmaceutical Design Sirtuins: Multifaceted Drug Targets
Current Molecular Medicine NF-κB Signaling Pathway Inhibitors as Anticancer Drug Candidates
Anti-Cancer Agents in Medicinal Chemistry Novobiocin Analogs as Potential Anticancer Agents
Mini-Reviews in Medicinal Chemistry WT1 Peptide Vaccine as a Paradigm for “Cancer Antigen-Derived Peptide”-Based Immunotherapy for Malignancies: Successful Induction of Anti-Cancer Effect by Vaccination with a Single Kind of WT1 Peptide
Anti-Cancer Agents in Medicinal Chemistry Steroid Resistance in Severe Asthma: Current Mechanisms and Future Treatment
Current Pharmaceutical Design Carbohydrates: Potential Sweet Tools Against Cancer
Current Medicinal Chemistry Synthesis and Characterization of Folic Acid Conjugated Gemcitabine Tethered Silver Nanoparticles (FA-GEM-AgNPs) for Targeted Delivery
Current Pharmaceutical Design Editorial (Thematic issue: Discovering New Anticancer Activities from Old Drugs)
Current Medicinal Chemistry The Combination of FDG PET/CT and Contrast Enhanced CT in the Evaluation of Recurrent Pancreatic Carcinoma and Cholangiocarcinoma
Current Medical Imaging Withdrawal Notice: Application of Nanomaterials in Development of Electrochemical Sensors and Drug Delivery Systems for Anticancer Drugs
Current Drug Delivery QT Prolongation and Anticancer Drugs: Is it a Cardiologist’s Worry? The Oncologist’s Point of View
Reviews on Recent Clinical Trials Anti-EGFR Binding Nanobody Delivery System to Improve the Diagnosis and Treatment of Solid Tumours
Recent Patents on Anti-Cancer Drug Discovery Stress-Activated MAP Kinase Cascades in Cellular Senescence
Current Medicinal Chemistry Subject Index to Volume 7
Combinatorial Chemistry & High Throughput Screening Metabolic Enzyme System and Transport Pathways in Chronic Kidney Diseases
Current Drug Metabolism